The scientific goal of the Cancer Immunology (Cl) Program at the Hollings Cancer Center (HCC) is to understand the basic mechanisms by which the immune system is regulated in cancer and to apply these discoveries to the development of immunotherapy trials. Led by Zihai Li, MD, PhD an immunologist and board-certified hematopoietic stem cell transplant physician, the Cl Program currently has 19 members representing 4 departments in the College of Medicine. Members hold 29 active grants (13 NCI) totaling $5.5M in annual total research project funding ($5.4M in peer-reviewed projects;$3.2M NCI), representing a 67% growth during this project period. The recruitment of 11 new scientists to the program since 2009 has greatly strengthened the breadth and depth of the science within the program. The three themes of the Cl Program are: ? Cancer Inflammation &Immune Tolerance: the role of inflammation and cross-talk between the innate and adaptive immune systems in cancer. ? T-Cell Biology &Therapy: T-cell mediated anti-tumor mechanisms and the development and optimization of novel cell-based therapies. ? Antibody, Complement, &Transplant-based Therapies: cross-cutting studies into antibody, complement, and transplant-based immunotherapeutic strategies. In the current funding period, the HCC Cl Program has clearly demonstrated success in nurturing groundbreaking basic research initiatives and has initiated several clinical applications from these findings. In the past five years, Cl Program members produced 119 cancer immunology-based publications with 29% of these representing inter-programmatic and 25% intra-programmatic collaborations and 45% from multiinstitutional collaborations.
The Hollings Cancer Center's Cancer Immunology Program is composed of 19 scientists representing multiple biomedical disciplines who are working together to understand the biology of the immune system and its role in the development and progression of cancer.
|Barton, Virginia; Armeson, Kent; Hampras, Shalaka et al. (2017) Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. Arch Dermatol Res 309:243-251|
|Alexander-Bryant, Angela A; Zhang, Haiwen; Attaway, Christopher C et al. (2017) Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo. Oral Oncol 72:123-131|
|Kim, Sungjin; Alsaidan, Omar Awad; Goodwin, Octavia et al. (2017) Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res 77:6950-6962|
|Yang, Aimin; Qin, Shenghui; Schulte, Bradley A et al. (2017) MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer. Cancer Res 77:6641-6650|
|Karam, Joseph A; Parikh, Rasesh Y; Nayak, Dhananjaya et al. (2017) Co-chaperone Hsp70/Hsp90-organizing protein (Hop) is required for transposon silencing and Piwi-interacting RNA (piRNA) biogenesis. J Biol Chem 292:6039-6046|
|Mehrotra, Shikhar; Britten, Carolyn D; Chin, Steve et al. (2017) Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 10:82|
|Sagar, Amin; Arif, Ehtesham; Solanki, Ashish Kumar et al. (2017) Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function. Sci Rep 7:12047|
|Liu, Qinlong; Rehman, Hasibur; Krishnasamy, Yasodha et al. (2017) 8-pCPT-cGMP prevents mitochondrial depolarization and improves the outcome of steatotic partial liver transplantation. Int J Physiol Pathophysiol Pharmacol 9:69-83|
|Ghatak, Shibnath; Hascall, Vincent C; Markwald, Roger R et al. (2017) Transforming growth factor ?1 (TGF?1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. J Biol Chem 292:10490-10519|
|Lemasters, John J (2017) Evolution of Voltage-Dependent Anion Channel Function: From Molecular Sieve to Governator to Actuator of Ferroptosis. Front Oncol 7:303|
Showing the most recent 10 out of 369 publications